Sandoz launches generic version of INTUNIV® extended release tablets in the US

Princeton, New Jersey, June 4, 2015 – Sandoz today announced the US market introduction of guanfacine hydrochloride extended release tablets, a generic version of INTUNIV®, which is currently marketed by Shire Pharmaceuticals.

Guanfacine hydrochloride extended release is a central alpha2A-adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. Guanfacine is not a central nervous system (CNS) stimulant. The mechanism of action of …

/by

Sandoz Poland celebrates the opening of a new packaging plant in Stryków

Stryków, May 07, 2015 – Sandoz, the generic Division of Novartis is announcing today the opening of the Sandoz Packaging Centre in Stryków – a project valued at 171 million PLN. It is one of the largest investment projects in the Polish pharmaceutical sector completed in recent years. Thanks to the expansion of the existing plant in Stryków, 90 new jobs have been created to date, soon to be followed by at least 40 additional ones. The opening ceremony was attended by government officials, including Deputy Prime Minister Janusz Piechociński, local politicians, members of …

/by

Sandoz Poland celebrates the opening of a new packaging plant in Stryków

Stryków, May 07, 2015 – Sandoz, the generic Division of Novartis is announcing today the opening of the Sandoz Packaging Centre in Stryków – a project valued at 171 million PLN. It is one of the largest investment projects in the Polish pharmaceutical sector completed in recent years. Thanks to the expansion of the existing plant in Stryków, 90 new jobs have been created to date, soon to be followed by at least 40 additional ones. The opening ceremony was attended by government officials, including Deputy Prime Minister Janusz Piechociński, local politicians, members of …

/by

Novartis delivered sales growth (cc), significant margin expansion(cc) and strong innovation in Q1; now with a more focused portfolio

Basel, April 23, 2015 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Our focus on execution has resulted in a strong operational performance. We have completed the GSK and Lilly transactions and innovation continues to be strong. We had three approvals in Oncology, FDA priority review for LCZ696, Zarxio became the first biosimilar approved under the new pathway in the US and we launched Cosentyx globally. We are on track to deliver our full-year guidance.”

 

  • Continuing operations1 saw sales, core2  …
/by

Innovative respiratory inhaler Airflusal® Forspiro® receives Alufoil Trophy 2015

April 16, 2015 – AirFluSal® Forspiro®, an innovative respiratory inhaler from Sandoz, has won the coveted Alufoil Trophy 2015 in the Product Preservation category. The inhaler uses a specially designed alufoil blister strip, which was developed by Amcor Flexibles, that ensures a longer shelf life of the inhalation powder.

This recognition for technical innovation is the second award for AirFluSal® Forspiro®. In 2011, the device received the Red Dot Product Design Award, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in …

/by

Sandoz receives FDA approval for Glatopa™ as the first generic competitor to MS therapy Copaxone® 20mg

  • Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis
  • Novartis and Sandoz are driving access to a full range of differentiated, high-quality MS therapeutic options, complemented by a full range of support services

Holzkirchen, Germany, April 16, 2015 – Sandoz, a Novartis company, today announced the US approval of GlatopaTM, the first generic version of Teva’s Copaxone® (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy.

“Sandoz …

/by

Sandoz launches authorized generic version of EXFORGE® in the US

Princeton, New Jersey, March 31, 2015 – Sandoz today announced the US market introduction of amlodipine and valsartan combination tablets, a generic version of EXFORGE® made by Novartis.

Amlodipine and valsartan tablets are a combination of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB).

Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure:

  • in patients not adequately controlled on monotherapy with a DHP CCB or an ARB
  • …
/by

Sandoz launches authorized generic version of EXFORGE® in the US

Princeton, New Jersey, March 31, 2015 – Sandoz today announced the US market introduction of amlodipine and valsartan combination tablets, a generic version of EXFORGE® made by Novartis.

Amlodipine and valsartan tablets are a combination of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB).

Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure:

  • in patients not adequately controlled on monotherapy with a DHP CCB or an ARB
  • …
/by

Sandoz receives approvals in Ireland and Sandoz launches innovative respiratory inhaler AirFluSal® Forspiro® in Portugal and Ireland

  • Sandoz launches 50-250 and 50-500µg dosage forms in Portugal and Ireland
  • Innovative inhaler offers asthma and COPD patients a new therapeutic option
  • Now available to patients in 14 countries, as global roll-out continues apace

Holzkirchen, March 11, 2015 – Sandoz today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.

AirFluSal, which was first approved in Denmark, has now been launched in a …

/by

Sandoz receives approvals in Ireland and Sandoz launches innovative respiratory inhaler AirFluSal® Forspiro® in Portugal and Ireland

  • Sandoz launches 50-250 and 50-500µg dosage forms in Portugal and Ireland
  • Innovative inhaler offers asthma and COPD patients a new therapeutic option
  • Now available to patients in 14 countries, as global roll-out continues apace

Holzkirchen, March 11, 2015 – Sandoz today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.

AirFluSal, which was first approved in Denmark, has now been launched in a …

/by